CytomX Therapeutics (NASDAQ:CTMX) CFO Christopher Ogden Sells 19,323 Shares of Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Christopher Ogden sold 19,323 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $124,053.66. Following the sale, the chief financial officer directly owned 296,948 shares in the company, valued at $1,906,406.16. The trade was a 6.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

CytomX Therapeutics Stock Down 2.2%

CTMX stock opened at $4.68 on Friday. The company’s fifty day simple moving average is $5.28 and its 200 day simple moving average is $4.10. CytomX Therapeutics, Inc. has a 12-month low of $0.40 and a 12-month high of $8.21. The firm has a market cap of $795.64 million, a price-to-earnings ratio of -118.50 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The company had revenue of $0.66 million for the quarter, compared to the consensus estimate of $7.33 million. CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%. Research analysts expect that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current year.

CytomX Therapeutics News Roundup

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Barclays raised its price target to $16 and moved CTMX to “overweight,” giving investors a high‑profile bullish thesis that likely contributed to buying interest. Barclays price-target raise
• Positive Sentiment: Guggenheim increased its forecast/price target (joined by other firms raising targets), reinforcing optimistic expectations for the pipeline and supporting the uptick. Guggenheim Forecasts Strong Price Appreciation for CytomX
• Positive Sentiment: Wedbush (and other sell‑side shops) also lifted price targets in the same window, creating a cluster of upgrades that appear to be driving momentum. Wedbush Raises Price Target
• Positive Sentiment: Trading volume spiked after the analyst upgrade cycle, indicating the upgrades translated into real buying rather than just headlines. Strong Trading Volume After Analyst Upgrade
• Neutral Sentiment: CytomX priced an equity offering for roughly $234 million — this materially extends runway but will be dilutive, so its net impact is mixed for shareholders. Equity Offering Announcement
• Negative Sentiment: CTMX recently missed quarterly estimates (EPS and revenue), a near‑term negative that adds volatility and raises questions about current execution vs. investor expectations. Shares Down on Disappointing Earnings
• Negative Sentiment: An analyst trimmed the Q1 EPS forecast, increasing uncertainty around near‑term results and guidance. Q1 EPS Forecast Decreased
• Negative Sentiment: Several insiders — including CEO Sean McCarthy (sold ~118,969 shares for ~$763,780) plus CFO and other senior execs — sold stock on March 17; while sales can be routine, clustered insider selling can sap sentiment. Insider Sales Report
• Negative Sentiment: At least one sell‑side commentary cautioned that early clinical data may not fully justify elevated valuation, adding a note of skepticism for momentum traders. Seeking Alpha valuation caution

Hedge Funds Weigh In On CytomX Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CTMX. Wells Fargo & Company MN raised its holdings in CytomX Therapeutics by 83.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares in the last quarter. Farther Finance Advisors LLC purchased a new position in shares of CytomX Therapeutics during the third quarter valued at about $25,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of CytomX Therapeutics during the fourth quarter valued at about $35,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in CytomX Therapeutics in the third quarter worth about $34,000. Finally, May Hill Capital LLC bought a new position in CytomX Therapeutics in the fourth quarter worth about $46,000. 67.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CTMX has been the subject of a number of research reports. Wedbush boosted their target price on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the company an “outperform” rating in a report on Tuesday. Guggenheim lifted their price target on CytomX Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday. Oppenheimer reiterated an “outperform” rating and set a $12.00 price objective on shares of CytomX Therapeutics in a research note on Monday. Jefferies Financial Group raised their target price on CytomX Therapeutics from $8.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Cantor Fitzgerald lifted their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, CytomX Therapeutics has an average rating of “Moderate Buy” and an average price target of $13.22.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.